GlaxoSmithKline plc
GSK.SW
Swiss Exchange19.98
CHF
- -
- -
GlaxoSmithKline plc
GSK.SW
(Swiss Exchange)
Recent
price
19.98
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- GlaxoSmithKline plc (GSK plc) is a British multinational biopharma company that discovers, develops, manufactures and markets specialty medicines, vaccines and general medicines focused on immunology, respiratory diseases, oncology, HIV and infectious diseases; its specialty medicines portfolio includes treatments for HIV such as Dovato and Cabenuva, respiratory conditions like Nucala and Trelegy Ellipta, immunology therapies for lupus and other immune-mediated diseases, and oncology products including Zejula and Blenrep; its vaccines portfolio comprises more than 20 marketed vaccines targeting infectious diseases across all life stages, such as Shingrix for shingles, Arexvy for RSV, and others for meningitis, hepatitis and influenza; general medicines feature inhalers for asthma and COPD like Advair/Seretide, antibiotics and dermatological treatments. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, GSK plc maintains global headquarters in London, England, and operates research, manufacturing and commercial activities across more than 115 countries, including major facilities in the United States at Research Triangle Park, North Carolina, and Philadelphia, Pennsylvania. In recent developments, GSK plc acquired IDRx in 2025 for $1.15 billion to bolster its gastrointestinal oncology portfolio with IDRX-42; entered strategic multi-program collaborations with Relation Therapeutics in December 2024 for fibrotic diseases and osteoarthritis targets, including $45 million upfront; acquired exclusive rights from Syndivia in October 2025 for a next-generation antibody-drug conjugate in prostate cancer for £268 million; announced a $30 billion investment over five years in U.S. R&D, manufacturing and clinical trials, including a new biologics facility in Pennsylvania; completed acquisition of Aiolos Bio in 2024 for over $1 billion to enhance respiratory treatments; and relocated its headquarters to New Oxford Street in central London in July 2024 while appointing Luke Miels as incoming CEO effective early 2026.